汉氏联合品牌怎么样 申请店铺

北京汉氏联合生物技术股份有限公司(简称“汉氏联合”)成立于2007年，是国家认定的高新技术企业。作为干细胞产业领域的先锋企业，汉氏联合致力于人类生命健康发展，以干细胞再生医学技术为核心，逐步形成以围产期干细胞存储、细胞及再生医学技术开发、药物研发为主导的科技平台，以精准再生医学、健康管理、医院集团、教育培训、生物护肤及国际医疗旅游为主导的医疗健康平台，旨在打造干细胞再生医学全产业链闭环。

目前，汉氏联合已在全国发展布局19家子公司，2015年，集团在法国建立了首家海外子公司-法国汉氏联合(H&B France)，成功跻身国际市场。汉氏联合集团聚集了一批国家级乃至国际级专家和科技人员，科研团队凭借强大的研发实力，自主研发几十项专利技术并多次创造行业记录，研究成果荣获国家科技进步一等奖和二等奖各1项、10余项省部级科技进步一等奖和二等奖。

自90年代至今，以董事长韩忠朝院士为代表的科研团队成功倡导三次围产期干细胞技术革命，成为国内甚至全球范围内围产期干细胞技术研发的风向标。汉氏联合集团在中国开创了同时可以保存多种胎盘组织源干细胞的干细胞银行，截至2019年，汉氏联合按各省市要求在北京、天津、山东、广东、福建、江西与贵州建设7家干细胞库。

一直以来，汉氏联合都专注于干细胞新药研发领域。2011年，汉氏联合集团在全球范围内率先发明以基于胎盘间充质干细胞移植治疗II型糖尿病技术，还开展了胎盘组织来源的造血干细胞的临床转化。基于汉氏联合的研发技术，共自主研发了10余款干细胞新药。2019年，集团自主研发的1类新药“人胎盘间充质干细胞凝胶”获得国家食品药品监督管理总局（NMPA）临床试验默示许可，这是全球第一款以活的胎盘间充质干细胞与生物材料混合制备的皮肤外用药物。此外，汉氏联合研发的注射用生物制品“注射用间充质干细胞（脐带)”新药也获NMPA受理；“高活性间充质干细胞注射液” I/IIa期于2019年获得法国药监局（ANSM）临床试验许可。

在精准再生医学领域，公司致力于干细胞再生医学、肿瘤细胞分型、遗传筛查、免疫细胞治疗、循环肿瘤细胞（CTC）和循环肿瘤DNA（ctDNA）等精准医学和临床转化医学的研究。汉氏联合借鉴美国梅奥医疗中心的经验，正在打造以医疗服务为中心的汉氏联合医学平台，包括生命科学院(本科院校)、三级医院、综合门诊部、体检中心、临检中心及互联网+医院。

汉氏联合集团以“干细胞再生医学技术产品”、“干细胞技术服务”以及“精准医疗服务”三大业务为核心板块，采用科学的资源整合、先进的运营模式、“以人为本”的价值理念，打造民族品牌的“产、学、研、医、养、美”联合体，引领再生医学产业，为人民提供优质的医疗健康服务。

Founded in 2007, Beijing Hanshi United Biotechnology Co., Ltd. (hereinafter referred to as "Hanshi united") is a high-tech enterprise recognized by the state. As a pioneer in the field of stem cell industry, Hans United is committed to the healthy development of human life. With stem cell regenerative medicine technology as the core, it has gradually formed a technology platform dominated by perinatal stem cell storage, cell and regenerative medicine technology development, and drug research and development, with precision regenerative medicine, health management, hospital group, education and training, biological skin care and international medical treatment Tourism as the leading medical and health platform aims to create a closed-loop of the whole industry chain of stem cell regenerative medicine. At present, Heinz Union has developed 19 subsidiaries in China. In 2015, the group established the first overseas subsidiary in France, H & bfrance, and successfully entered the international market. Hanshi United Group has gathered a group of national and even international experts and scientific and technological personnel. With strong R & D strength, the scientific research team independently researched and developed dozens of patented technologies and created industry records for many times. The research results have won the first and second prizes of national science and technology progress, respectively, and more than 10 provincial and ministerial science and technology progress first and second prizes. Since the 1990s, the research team, represented by academician Han Zhongchao, chairman of the board of directors, has successfully advocated three revolutions of perinatal stem cell technology, becoming the wind vane of research and development of perinatal stem cell technology at home and even around the world. Han's joint group has created a stem cell bank in China that can simultaneously store a variety of placenta derived stem cells. By 2019, Han's joint group has built seven stem cell banks in Beijing, Tianjin, Shandong, Guangdong, Fujian, Jiangxi and Guizhou according to the requirements of various provinces and cities. For a long time, Hamilton Union has been focusing on the research and development of new stem cell drugs. In 2011, Hans group took the lead in the world in inventing the technology of treating type II diabetes mellitus based on placental mesenchymal stem cell transplantation, and also carried out the clinical transformation of placental tissue-derived hematopoietic stem cells. Based on the joint research and development technology of Hans, more than 10 new stem cell drugs have been independently developed. In 2019, the group's 1 new drugs, "human placental mesenchymal stem cell gel", were granted the permission of the national food and Drug Administration (NMPA) clinical trial. This is the world's first skin topical drug produced by the combination of living placenta derived mesenchymal stem cells and biomaterials. In addition, the new drug "mesenchymal stem cells for injection (umbilical cord)" jointly developed by Hans has also been accepted by nmpa; the phase I / IIA of "highly active mesenchymal stem cells injection" has obtained the clinical trial license of ansm in 2019. In the field of precision regenerative medicine, the company is committed to stem cell regenerative medicine, tumor cell typing, genetic screening, immune cell therapy, circulating tumor cells (CTC) and circulating tumor DNA (ctDNA) and other precision medicine and clinical transformation medicine research. Han's experience from the Mayo Medical Center in the United States is building a medical center for the Han's joint medical platform, including the Life Sciences Academy (undergraduate), three level hospital, comprehensive outpatient department, physical examination center, clinical examination center and Internet plus hospital. Hanshi united group takes "stem cell regenerative medical technology products", "stem cell technology services" and "precision medical services" as its core businesses, adopts scientific resource integration, advanced operation mode and "people-oriented" value concept to build a national brand "production, learning, research, medicine, nutrition and beauty" consortium, leading the regenerative medical industry and serving the people Provide quality medical and health services.

本文链接： https://brand.waitui.com/c5adab6e2.html 联系电话：13521917728